Apollomics racks up $100 mln Series B

Apollomics Inc, a biopharmaceutical company focused on oncology combination therapies, has raised $100 million in Series B financing. CMB International led the round with participation from other investors that included OrbiMed Asia.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!